TITLE

SATRAPLATIN SPARC PHASE 3 PROSTATE CANCER DATA REPORTED

PUB. DATE
July 2008
SOURCE
Worldwide Biotech;Jul2008, Vol. 20 Issue 7, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article details the survival results of the Phase 3 SPARC trial (Satraplatin and Prednisone Against Refractory Cancer) conducted by GPC Biotech AG. The company presented the clinical trial results at the 44th Annual Meeting of the American Society for Clinical Oncology in Chicago, Illinois. Satraplatin plus prednisone is a new therapy for hormone-refractory prostate cancer. The tests show that the survival results did not improve, but there was significant improvement in pain, tumor and PSA response rates.
ACCESSION #
32848004

 

Related Articles

  • American Society of Clinical Oncology.  // BioWorld Today;6/3/2009, Vol. 20 Issue 105, p5 

    The article highlights the Phase III Satraplatin and Prednisone Against Refractory Cancer (SPARC) trial presented by GPC Biotech AG at the 2009 American Society of Clinical Oncology (ASCO) annual meeting. The trial compares satraplatin plus prednisone and placebo plus prednisone in patients...

  • Celgene Calls it Quits in GPC Satraplatin Deal. Young, Donna // BioWorld Today;8/8/2008, Vol. 19 Issue 154, p1 

    The article reports on the ending of the partnership established by Celgene Corp. with GPC Biotech AG for its prostate cancer drug satraplatin. Celgene has retracted its European marketing application for the drug, which is combined with prednisone to manage prostate cancer. GPC reveals that its...

  • GPC Biotech reports positive data from Phase III cancer trial.  // PharmaWatch: Cancer;Apr2009, Vol. 8 Issue 4, p15 

    The article focuses on the significance of the Sparc trial conducted by the GPC Biotech AG. As stated, the Sparc trial evaluated satraplatin plus prednisone versus placebo plus prednisone in 950 patients with androgen-independent or castraterefractory prostate cancer (CRPC) who had passed after...

  • GPC Biotech receives clearance from FDA to begin phase III registrational trial of satraplatin.  // PharmaWatch: Cancer;October 2003, Vol. 2 Issue 10, p13 

    Reports that GPC Biotech AG has received written confirmation from the United States Food and Drug Administration (FDA) that the company may initiate a phase III registrational trial with satraplatin plus prednisone in patients with hormone-refractory prostate cancer who have failed prior...

  • GPC Biotech Withdraws Satraplatin NDA -- For Now. Sheridan, Cormac // BioWorld International;8/1/2007, Vol. 12 Issue 31, p1 

    The article reports that GPC Biotech AG in Martinsried, Germany, withdrew its new drug application (NDA) for accelerated approval of satraplatin in hormone refractory prostate cancer. The company said that it would resubmit an NDA with overall survival data from its 950-patient Phase III...

  • Algeta's Alpharadin Boosts Survival In Prostate Cancer. Boggs, Jennifer // BioWorld Today;9/26/2007, Vol. 18 Issue 187, p3 

    The article reports that Algeta ASA will start Phase III trials of its alpha emitter Alpharadin after showing data that the drug improves prostate cancer survival rate over placebo. Trials results showed that Alpharadin delayed the disease progression in patients with hormone-refractory prostate...

  • GPC Biotech expands Satraplatin phase III trial.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p13 

    Reports that GPC Biotech received a Scientific Advice letter from the European Agency for the Evaluation of Medicinal Products, enabling it to proceed with its registrational plans in Europe using the Satraplatin and Prednisone Against Refractory Cancer trial. Trial evaluation of Satrapaltin...

  • GPC Biotech expands Satraplatin phase III trial.  // PharmaWatch: Biotechnology;March 2004, Vol. 3 Issue 3, p5 

    Reports on the expansion of satraplatin phase III trial of GPC Biotech AG in Europe. Demonstration of the safety and efficacy of medicinal products; Completion of a Special Protocol Assessment by the Food abd Drug Administration; Treatment of patients with hormone-refractory prostate cancer.

  • Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice. Yan, Shang-xue; Deng, Xiao-mei; Wang, Qing-tong; Sun, Xiao-jing; Wei, Wei // Acta Pharmacologica Sinica;Nov2015, Vol. 36 Issue 11, p1367 

    Aim:A number of evidence shows that the differentiation of B lymphocytes into plasma cells plays an important role in lupus pathogenesis. In this study we investigated how prednisone, a classical therapeutic drug for autoimmune diseases, regulated plasma cell differentiation in MRL/MpSlac-lpr...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics